AGEN2034
Phase 2Small molecule
AGEN2034 is one of 91 small molecule programs targeting Angiosarcoma. It is currently in Phase 2.
3
Indications
5
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
380 competitors in Cervical Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Paraplatin
AAvyxa
Phase 3
Hycamtin
MMeitheal
Phase 3
Hycamtin
GGynecologic Oncology Group
Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Epoetin Beta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer2 trials
Bladder Cancer1 trial
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04430036·4 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AGEN2034. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRottapharm Biotech